AMBITION

October 26, 2015November 5, 2015

GSK’s Volibris (Ambrisetan) Indication Expanded for PAH in Europe After CHMP Positive Opinion

GSK, a world leading research-based pharmaceutical and health care company, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has released a ... Read more

August 31, 2015November 5, 2015

Gilead Sciences Publishes Data From AMBITION Study of Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, Inc., a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs, recently announced detailed data from its AMBITION randomized, double-blind, multicenter ... Read more

December 12, 2014November 5, 2015

GSK Submits Ambrisentan for PAH Treatment to European Medicines Agency

News, Pulmonary Hypertension

Research-based pharmaceutical and healthcare company GSK has completed regulatory submission to the European Medicines Agency (EMA) regarding a series of Marketing Authorizations for ambrisentan (Volibris), their therapy for pulmonary arterial hypertension (PAH). ... Read more